Resumen: Incyte anuncia que los nuevos datos positivos en EHA 2026 demostraron que INCA033989 logró respuestas clínicas y moleculares rápidas, robustas y sostenidas, y fue bien tolerado por pacientes con mielofibrosis y trombocitemia esencial
Monday, June 15, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Incyte announced positive new data from EHA 2026 regarding INCA033989, which demonstrated rapid, robust, and sustained clinical and molecular responses in patients with myelofibrosis and essential thrombocythemia. The treatment was well tolerated, indicating its potential effectiveness in these conditions.
Price reaction · baseline $103.29 (2026-06-15T15:40:00.000Z) · hit during market hours · 2 other INCY headline(s) in the window, move may be shared
day 0 close · peak
-1.3%
Market Sentiment Analysis
POSITIVE FACTORS
New data shows rapid and robust clinical responses.
INCA033989 was well tolerated by patients.
The results indicate sustained responses in patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
INCB013739
Phase 2 · Type 2 Diabetes
Full Press Release Details
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) anunció hoy datos clínicos actualizados de dos estudios fase 1 que evalúan la seguridad, la tolerabilidad y la eficacia de INCA033989, el primer anticuerpo monoclonal dirigido contra la calreticulina mutada (mutCALR) de su clase, en pacientes con neoplasias mieloproliferativas (MPN) con expresión de mutCALR.
El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original, que es la única versión del texto que tendrá validez legal.
Frequently Asked Questions
What is INCA033989?
INCA033989 is a treatment developed by Incyte for myelofibrosis and essential thrombocythemia.
What were the results from EHA 2026?
The results showed rapid, robust, and sustained clinical responses in patients.
How was INCA033989 tolerated by patients?
The treatment was reported to be well tolerated by patients.
What conditions does INCA033989 target?
INCA033989 targets myelofibrosis and essential thrombocythemia.